PTN Company Financial Information

Symbol Info
Palatin Technologies Inc. (PTN)
Listed Symbol	PTN
Name	Palatin Technologies Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share	$-
Latest Fiscal Date	2019-06-30
Latest Fiscal Revenue	$60,300,476
Latest Fiscal EPS	$0.16
Price Info
21 Day Moving Average	$0.8653
21 Day EMA	$0.864760
50 Day Moving Average	$0.9045
50 Day EMA	$0.908880
200 Day EMA	$0.983970
200 Day Moving Average	1.002600
52 Week High	$1.78
52 Week Low	$0.59
52 Week Change	$-10.002200
Alpha	0.012719
Beta	1.8256
Standard Deviation	0.221067
R2	0.080430
Periods	60
Share Information
10 Day Average Volume	667,126
20 Day Average Volume	921,629
30 Day Average Volume	1,345,492
50 Day Average Volume	1,136,555
Outstanding Shares	227,039,363
Float Shares	211,733,134
Percent Float	93.26%
Short Interest	24,843,229
Short Percent Float	10.90%
Short Interest Ratio	16.04
Short Date	2019-09-30
Holders
Institutions	162
Institute Holdings Date	2019-09-30
Institute Bought Previous 3 Months	4,723,461
Institute Holdings Percent	32.400000
Institute Sold Previous 3 Months	4,022,105
Insider Holdings Date	2019-08-31
Insider Bought Previous 3 Months	28
Insider Holdings Percent	7.10%
Insider Sold Previous 3 Months	-
Insiders Shares Owned	15,306,229
Price Change
7 Day Price Change	$0.0062000
7 Day Percent Change	0.75%
21 Day Price Change	$-0.0551
21 Day Percent Change	-6.21%
30 Day Price Change	$-0.1151
30 Day Percent Change	-12.15%
Month To Date Price Change	$-0.0765
Month To Date Percent	-8.42%
90 Day Price Change	$-0.1623
90 Day Percent Change	-16.32%
Quarter To Date	$-0.0765
Quarter To Date Percent	-8.42%
180 Day Price Change	$-0.2277
180 Day Percent Change	-21.48%
200 Day Price Change	$-0.1677
200 Day Percent Change	-16.77%
Year To Date	$0.123900
Year To Date Percent	17.49%
Profile
Description	Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
Details
Issue Type	CS
Market Cap	$188,964,862
Sec Type	EQS
Auditor	KPMG LLP
Total Shares Outstanding	227,039,363
CEO	Carl Spana
Employees	18
Last Audit	UE
Classification
CIK	0000911216
Industry	Medical Diagnostics & Research
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)
Info
Address	4B Cedar Brook Drive Cranbury, NJ 8512
Website	https://www.palatin.com
Facisimile	+1 609 495-2202
Telephone	+1 609 495-2200
Email	investors@palatin.com
Key Ratios
Profitability
EBIT Margin	60.00
EBITDA Margin	60.1
Pre-Tax Profit Margin	-
Profit Margin Cont	68.79
Gross Margin	-
Profit Margin TOT	68.79
Income Statements
Revenue	$60,265,971
Revenue Per Share	$0.2654
Revenue 3 Years	$-
Revenue 5 Years	$-
Valuation Measures
PE Ratio	5.40
Enterprise Value	$163,155,887
Price To Sales	3.135515
Price To Free Cash	-12.1
PE High Last 5 Years	-
Price To Book	2.0
Price To Cash Flow	109.4
PE Low Last 5 Years	-
Price To Tangible Book	2.0
Financial Strength
Total Debt To Equity	-
Int Coverage	86.7
Current Ratio	24.9
Leverage Ratio	1.1
Quick Ratio	24.8
Long Term Debt To Capital	-
Assets
Receivables Turnover	2.0
Invoice Turnover	-
Assets Turnover	0.50
Management Effectiveness
Return Assets	49.77
Return On Equity	56.11
Return On Capital	54.10
Dividends
Dividend 3 Years	$-
Dividend 5 Years	$-
Ex Dividend Date
Dividend Rate	$-
Dividend Yield	-
Payment Type